二十碳五烯酸在心血管疾病中的相关研究及临床应用

doi:10.3969/j.issn.1004-583X.2025.06.015

摘要/Abstract

摘要：

他汀类药物是防治心血管疾病的基石,然而部分患者经规范治疗后仍存在心血管疾病残余危险。多个研究表明,高甘油三酯水平是他汀类药物治疗后心血管疾病残余风险的关键要素。二十碳五烯酸属于ω-3型多不饱和脂肪酸,可通过多种机制降低甘油三酯水平、发挥抗动脉粥样硬化的作用。本文从二十碳五烯酸主要的作用机制、在心血管疾病方面相关的重要研究及其临床应用方面进行概述。

中图分类号:

R541.4

曹淑风, 杨昌林. 二十碳五烯酸在心血管疾病中的相关研究及临床应用[J]. 临床荟萃, 2025, 40(6): 564-569.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2025.06.015

https://lchc.magtechjournal.com/CN/Y2025/V40/I6/564

参考文献 38

[1]	Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study[J]. J Am Coll Cardiol, 2020, 76 (25): 2982-3021. doi: 10.1016/j.jacc.2020.11.010 pmid: 33309175
[2]	国家心血管病中心. 中国心血管健康与疾病报告2021[M]. 北京: 科学出版社, 2022.
[3]	Boden WE, Bhatt DL, Toth PP, et al. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCEIT trial: Why these results usher in a new era in dyslipidaemia therapeutics[J]. Eur Heart J, 2020, 41(24): 2304-2312.
[4]	Libby P. The changing landscape of atherosclerosis[J]. Nature, 2021, 592(7855): 524-533.
[5]	Dhindsa DS, Sandesara PB, Shapiro MD, et al. The evolving understanding and approach to residual cardiovascular risk management[J]. Front Cardiovasc Med, 2020, 7: 88. doi: 10.3389/fcvm.2020.00088 pmid: 32478100
[6]	Nichols GA, Philips S, Reynolds K, et al. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controled LDL cholesterol[J]. Diabetes Obes Metab, 2019, 21(2): 366-371.
[7]	Oscarsson J, Hurt-camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: A review[J]. Lipids Health Dis, 2017, 16(1): 149.
[8]	Lorente-cebrian S, Bustos M, Marti A, et al. Eicosapentaenoic acid inhibits tumour necrosis factor-a-induced lipolysis inmurine cultured adipocytes[J]. J Nutr Biochem, 2012, 23(3): 218-227. doi: 10.1016/j.jnutbio.2010.11.018 pmid: 21497077
[9]	Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors[J]. Mol Cell, 1999, 3(3):397-403. doi: 10.1016/s1097-2765(00)80467-0 pmid: 10198642
[10]	Vosper H, Khoudoli GA, Graham TL, et al. Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis[J]. Pharmacol Ther, 2002, 95(1): 47-62.
[11]	Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasmaapolipoprotein C-III levels in patients from the MARINE and ANCHOR studies[J]. J Clin Lipidol, 2016, 10(3): 635-645. doi: 10.1016/j.jacl.2016.02.008 pmid: 27206952
[12]	Mason RP, Sherratt SCR, Eckel RH. Omega-3-fatty acids: Do they prevent cardiovascular disease?[J]. Best Pract Res Clin Endocrinol Metab, 2023, 37(3): 101681.
[13]	Pareek M, Mason RP, Bhatt DL. Icosapent ethyl: Safely reducing cardiovascular risk in adults with elevated triglycerides[J]. Expert Opin Drug Saf, 2022, 21(1): 31-42.
[14]	Zambon A, Pirillo A, Zambon S, et al. Omega n-3 supplementation:exploring the cardiovascular benefits beyond lipoprotein reduction[J]. Curr Atheroscler Rep, 2020, 22(12): 74.
[15]	Borghi C, Bragagni A. Clinical results and mechanism of action of icosapent ethyl[J]. Eur Heart J Suppl, 2023, 25(Suppl B):B37-B40.
[16]	Sutariya B, Montenegro DM, Chukwu M, et al. Emphasis on icosapent ethyl for cardiovascular risk reduction: A systematic review[J]. Cureus, 2022, 14(12): e32346.
[17]	Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases[J]. J Am C0ll Nutr, 2002, 21(6): 495-505.
[18]	Chapman MJ, Zamorano JL, Parhofer KG. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid[J]. Pharmacol Ther, 2022, 237: 108172.
[19]	Tadic M, Cuspidi C. The therapy with icosapent ethyl after the EVAPORATE trial: Between hope and skepticism[J]. J Clin Hypertens, 2020, 22(12): 2382-2384.
[20]	Konishi T, Sunaga D, Funayama N, et al. Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging[J]. Clin Cardiol, 2019, 42(6): 618-628. doi: 10.1002/clc.23185 pmid: 30993750
[21]	Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins[J]. J Cardiol, 2017, 70(6): 537-544. doi: S0914-5087(17)30200-9 pmid: 28863874
[22]	GISSI-Prevenzione Investigators (Gruppo Italiano per Io Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial[J]. Lancet, 1999, 354 (9177): 447-455.
[23]	Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS):A randomised open-label, blinded endpoint analysis[J]. Lancet, 2007, 369(9567): 1090-1098.
[24]	Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of N-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF Trial): A randomised, double-blind, placebo-controlled trial[J]. Lancet, 2008, 372(9645): 1223-1230. doi: 10.1016/S0140-6736(08)61239-8 pmid: 18757090
[25]	Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J]. N Engl J Med, 2019, 380(1): 11-22.
[26]	Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction a randomized, controlled trial[J]. Circulation, 2021, 143(6): 528-539.
[27]	Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial[J]. JAMA, 2020, 324(22): 2268-2280. doi: 10.1001/jama.2020.22258 pmid: 33190147
[28]	Nishizaki Y, Miyauchi K, Iwata H, et al. Study protocol and baseline characteristics of randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and eicosapentaenoic acid:RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study[J]. Am Heart J, 2022, 257: 1-8. doi: 10.1016/j.ahj.2022.11.008 pmid: 36372250
[29]	Nelson JR, Raskin S. The eicosapentaenoic acid: Arachidonic acid ratio and its clinical utility in cardiovascular disease[J]. Postgrad Med, 2019, 131(4): 268-277. doi: 10.1080/00325481.2019.1607414 pmid: 31063407
[30]	Miyauchi K, Iwata H, Nishizaki Y, et al. Randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and eicosapentaenoic acid (RESPECT-EPA)[J]. Circulation, 2024, 150(6): 425-434. doi: 10.1161/CIRCULATIONAHA.123.065520 pmid: 38873793
[31]	Mach F, Baigent C, Carapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias:Lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1): 111-188
[32]	American Diabetes Association. Pharmacologic approaches to glycenic treatment: Standards of inedical care in diabetes-2020[J]. Diabetes Care, 2020, 43(Suppl 1): S98-S110.
[33]	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38(3): 237-269.
[34]	Roth EM, Bays HE, Forker AD, et al. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects[J]. J Cardiovasc Pharmacol, 2009, 54(3): 196-203. doi: 10.1097/FJC.0b013e3181b0cf71 pmid: 19597368
[35]	Shearer GC, Pottala JV, Hansen SN, et al. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: A randomized controlled trial[J]. J Lipid Res, 2012, 53(11): 2429-2435. doi: 10.1194/jlr.P022392 pmid: 22892157
[36]	Kelley DS, Adkins Y. Similarities and differences between the effects of EPA and DHA on markers of at39herosclerosis in human subjects[J]. Proc Nutr Soc, 2012, 71(2): 322-331.
[37]	Khan SU, Lone AN, Khan MS, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta analysis[J]. EClinical Medicine, 2021, 38: 100997.
[38]	国家心血管病专家委员会心血管代谢医学专业委员会. Omega-3脂肪酸在心血管疾病防治中的作用中国专家共识[J]. 中国循环杂志, 2023, 38(2): 116-130.

二十碳五烯酸在心血管疾病中的相关研究及临床应用

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张雪, 王俊祥. 类风湿关节炎共病的研究进展[J]. 临床荟萃, 2025, 40(1): 86-89.
[2]	张中楼, 崔坤, 孟晋启. 运动保护心血管系统的研究进展[J]. 临床荟萃, 2024, 39(9): 855-860.
[3]	马剑楠, 陶杰, 桑大森, 吴寿岭, 张旗. 尿转铁蛋白与2型糖尿病人群新发心血管疾病的关系[J]. 临床荟萃, 2024, 39(8): 700-705.
[4]	庞樱容, 孙欣. sST2在心血管疾病中作用的研究进展[J]. 临床荟萃, 2024, 39(5): 460-465.
[5]	王玉伟, 金迪, 付永兴, 刘志刚. 系统性红斑狼疮相关动脉粥样硬化研究进展[J]. 临床荟萃, 2024, 39(11): 1052-1056.
[6]	顾天舒, 梁雪, 蔡嘉庚, 李广平. m6A RNA甲基化修饰在心血管疾病中的进展[J]. 临床荟萃, 2023, 38(8): 743-748.
[7]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[8]	张怡, 崔晓冉, 杨晓红. 单核细胞/高密度脂蛋白胆固醇比值在心血管疾病中研究进展[J]. 临床荟萃, 2022, 37(6): 551-555.
[9]	张磊, 娄海东, 智昱, 亓树莹. PCSK9抑制剂对动脉粥样硬化性心血管疾病有效性及安全性的meta分析[J]. 临床荟萃, 2022, 37(12): 1074-1080.
[10]	杨瑞, 刘宇宏. 类风湿关节炎患者血脂水平与心血管疾病风险相关研究进展[J]. 临床荟萃, 2022, 37(1): 92-96.
[11]	叶蒙蒙, 李旎, 徐国栋, 邵国丰. miR-361在心血管疾病的研究进展[J]. 临床荟萃, 2021, 36(9): 843-849.
[12]	卢昊阳, 卢家忠, 韩明锋, 吕新才, 张标, 戎成振, 贾蕾蕾, 潘强强, 马蕾蕾, 赵韧. 新型冠状病毒肺炎合并心血管疾病的临床治疗观察[J]. 临床荟萃, 2021, 36(3): 203-207.
[13]	简郭进, 张斌. 沙库巴曲缬沙坦在心血管疾病中的研究进展[J]. 临床荟萃, 2021, 36(11): 1041-1045.
[14]	梁欢1，刘建凤2. 盘点钠-葡萄糖协同转运蛋白2抑制剂临床研究新进展[J]. 临床荟萃, 2020, 35(9): 861-864.
[15]	年士艳a，冯磊b. 云南省元江县傣族、哈尼族和彝族心血管病相关生化指标的差异性研究[J]. 临床荟萃, 2020, 35(8): 689-692.